Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Taiwan
  4. Taipei Exchange
  5. Lin BioScience, Inc.
  6. News
  7. Summary
    6696   TW0006696008

LIN BIOSCIENCE, INC.

(6696)
End-of-day quote Taipei Exchange  -  2022-09-29
219.00 TWD   -3.52%
08/12Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
04/24Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
SummaryQuotesChartsNewsCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

04/28/2020 | 08:04pm EDT

Lin BioScience, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was TWD 238.221 million compared to TWD 155.604 million a year ago. Net loss was TWD 235.256 million compared to TWD 138.516 million a year ago. Basic loss per share was TWD 3.95 compared to TWD 2.33 a year ago.


© S&P Capital IQ 2020
All news about LIN BIOSCIENCE, INC.
08/12Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
04/24Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021Lin Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
2021Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
2020Lin BioScience, Inc.(GTSM:6696) added to S&P Global BMI Index
CI
2020Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
2019Lin Bioscience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019
CI
2019Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
CI
More news
Financials
Sales 2021 - - -
Net income 2021 -435 M -13,7 M -13,7 M
Net cash 2021 805 M 25,3 M 25,3 M
P/E ratio 2021 -29,4x
Yield 2021 -
Capitalization 15 808 M 497 M 497 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 100,0%
Chart LIN BIOSCIENCE, INC.
Duration : Period :
Lin BioScience, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Yue Hsin Lin Chairman, Chief Executive Officer, GM & Spokesman
Hao Yuan Chuang Director, Spokesman, Head-Finance & Accounting
Cheng Chi Wang Head-Research & Development
Hung Wei Chen Chief Operating Officer & Head-Clinical Operations
Hui Chun Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIN BIOSCIENCE, INC.17.74%497
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296